## Genetically Predicted IL-18 Inhibition and Risk of Cardiovascular Events: A

# 2 Mendelian Randomization Study

- 4 Stephen Brennan, MB<sup>1,2</sup>, Peter J. Kelly MD<sup>1,3,4</sup>, Sarah Gorey, MB<sup>3</sup>, Pádraig Synnott, MB<sup>3</sup>,
- 5 Dipender Gill, MB,<sup>5</sup> Martin Dichgans, MD<sup>6,7,8</sup>, Marios Georgakis, PhD<sup>6,9,10</sup>, Marie-Joe Dib,
- 6 PhD<sup>11</sup>, Eloi Gagnon, MA<sup>12</sup>, Niall Mahon, MB<sup>13</sup>, Gavin Blake, MB<sup>13</sup>, Christina Jern, PhD<sup>14,15</sup>,
- Hugh S. Markus, PhD<sup>16</sup>, William Whiteley PhD<sup>17,18</sup>, John J. McCabe, PhD<sup>3,4,19</sup>.
- 9 1. Stroke Service, Department of Neurology, Mater Misericordiae University Hospital, Dublin,
- 10 Ireland

1

3

8

- 11 2. School of Medicine, University of Galway, Galway, Ireland
- 12 3. Health Research Board Stroke Clinical Trials Network Ireland, Dublin, Ireland,
- 4. School of Medicine, University College Dublin, Dublin, Ireland
- 14 5. Department of Epidemiology and Biostatistics, School of Public Health, Imperial College
- London, London, UK.
- 16 6. Institute for Stroke and Dementia Research, University Hospital, LMU Munich, Germany
- 17 7. German Center for Neurodegenerative Disease, Munich, Germany
- 18 8. Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
- 19 9. Center for Genomic Medicine, Massachusetts General Hospital, Boston, United States
- 20 10. Program in Medical and Population Genetics, Broad Institute of Harvard and the Massachusetts
- Institute of Technology, Boston, United States
- 22 11. Cardiovascular Division, Perelman School for Advanced Medicine, University of Pennsylvania,
- Philadelphia, USA.
- 24 12. Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Laval
- 25 University, Québec (QC), Canada
- 26 13. Department of Cardiology, Mater Misericordiae University Hospital, Dublin, Ireland

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

14. Department of Clinical Genetics and Genomics, Sahlgrenska University Hospital, Gothenburg, Sweden 15. Department of Laboratory Medicine, Institute of Biomedicine, the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden 16. Stroke Research Group, Department of Clinical Neuroscience, University of Cambridge, Cambridge, United Kingdom 17. Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom 18. Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom 19. Stroke Service, Department of Geriatric Medicine, Mater Misericordiae University Hospital, Dublin, Ireland Corresponding author: Stephen Brennan, MB, Stroke Service, Department of Neurology, Mater Misericordiae University Hospital, Dublin, Ireland T: +353-1-803-2000, E: stephenbrennan@mater.ie Total manuscript word count (including Title Page, Abstract, Text, References, and Figures Legends): 7033 

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

**Abstract Background:** Inflammation is an emerging target for the prevention and treatment of cardiovascular disease (CVD). This drug-target Mendelian randomization (MR) study aimed to predict the on-target effects of IL-18 inhibition on CVD risk. Furthermore, we aimed to explore the effects of IL-18 inhibition on cardio-metabolic traits, cardiac structure, and function, and identify potential adverse outcomes. **Methods:** We selected five independent circulating IL-18-lowering variants around the *IL-18* gene locus from the Systematic and Combined AnaLysis of Olink Proteins (SCALLOP) consortium. We then performed two-sample MR analyses to investigate the association of genetically proxied IL-18-inhibition on downstream inflammatory markers, risk of CVD, cardiac magnetic resonance (CMR) imaging measurements of cardiac structure and function, cardiometabolic traits, and a selection of potential adverse effects. We utilized data from the UK Biobank, Cardiogram, GIGASTROKE, and other large genomic consortia (sample range: 3,301-1,320,016). **Results:** Following correction for multiple comparisons, one standard deviation (SD) lower in genetically-predicted circulating IL-18 was associated with reductions in downstream biomarkers of IL-18 signaling, including C-reactive protein (SD change -0.02, 95% CI -0.03, -0.02), tumor necrosis factor (SD change -0.19, CI -0.25, -0.14), interferon-gamma (SD change -0.15, CI -0.22, -0.08), and CXCL10 (SD change -0.13, CI -0.16, -0.09). Lower genetically-predicted IL-18 levels were associated with reduced risk of cardio-embolic stroke (Odds Ratio [OR] 0.85, CI 0.79-0.92), but not other stroke subtypes. Furthermore, lower genetically predicted IL-18 levels were associated with reduced risk of peripheral arterial disease (OR 0.91, CI 0.84-0.97), atrial fibrillation (OR 0.94, CI 0.89-0.99), and heart failure

(OR 0.84, CI 0.77-0.92), as well as improvements in CMR traits, including a reduction in left atrial volume (\$\beta\$ -0.02, CI -0.03, -0.00). Lower genetically-predicted IL-18 levels were associated with lower risk of chronic kidney disease, autoimmune diseases, a favorable cardio-metabolic profile, and higher odds of lung cancer, but not infections. **Conclusions:** Our study provides genetic support that impaired IL-18 signaling may be causally associated with a lower risk of cardio-embolic stroke, possibly mediated through prevention of cardiac re-modelling, heart failure and atrial fibrillation. IL-18 represents a potential target for antiinflammatory therapy in stroke and CVD that warrants further investigation in clinical trials.

**Clinical Perspective** What is new? Using multi-omic data, this Mendelian Randomization study provides evidence that IL-18 lowering is associated with a lower lifetime risk of cardiac remodeling, heart failure, and cardio-embolic stroke. A significant proportion of the protective effect of impaired IL-18 signaling on cardioembolic stroke was mediated through a reduced risk of AF. What are the clinical implications? These data provide compelling evidence that the IL-18 signaling pathway is a promising druggable target for the treatment of heart failure and the prevention of cardio-embolic stroke. Several monoclonal antibodies targeting IL-18 are in development for the treatment of atopic dermatitis and could be considered for re-purposing for cardiovascular disease.

**Abbreviations** HF: Heart failure NLRP: NOD-like receptor family pyrin domain-containing AF: Atrial fibrillation IL-18: Interleukin-18 CMR: Cardiac magnetic resonance CRP: C-reactive protein IFN-γ: Interferon-gamma CVD: cardiovascular disease MR: Mendelian randomization GWAS: Genome-wide association study 

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

Introduction Inflammation has emerged as a promising target for the treatment of atherosclerosis and the secondary prevention of coronary events.<sup>1, 2</sup> The first anti-inflammatory trials for secondary prevention after stroke have primarily focused on the therapeutic potential of these agents in patients with atherosclerotic mechanisms and excluded patients with cardio-embolic stroke.<sup>3</sup> However, several complementary lines of evidence also support the importance of inflammatory mechanisms in the pathophysiology and progression of heart failure (HF), atrial fibrillation (AF), and cardio-embolic stroke. Animal models provide compelling data that the NOD-like receptor family pyrin domain-containing 3 (NLRP) inflammasome is upregulated in cardiomyocytes in the pathogenesis of AF and promotes structural and electrical atrial remodeling. Inflammatory signaling is implicated in several pathways central to the pathophysiology of HF, including mitochondrial dysfunction, calcium homeostasis, cardiac fibrosis, and impaired cardiomyocyte contractility. 5,6 Inflammatory markers are associated with incident AF in population-based studies<sup>7,8</sup> and AF-related stroke.<sup>9</sup> Despite these promising data, the results of the first RCTs of anti-inflammatory therapies in HF, 10, 11 and AF<sup>12</sup> have been neutral. The NLRP3 inflammasome mediates some of its effects through activation of interleukin-1β (IL-1β) via caspase-1 and leads to downstream IL-6 expression. Pre-clinical, <sup>13</sup> observational, <sup>14, 15</sup> and genetic studies <sup>16</sup> have coalesced to identify the IL-1β-interleukin-6 (IL-6) signaling pathway as a promising target for risk reduction in cardiovascular disease 17 and stroke. 18 Significantly less attention has been given to the role of interleukin-18 (IL-18), which is also cleaved to its active form by caspase-1 following activation by the NLRP3 inflammasome. 13 IL-18 is a potent pro-inflammatory cytokine that promotes atherosclerotic plaque progression in pre-clinical work. 13 However, experimental data have also

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

demonstrated that IL-18 signaling plays a key role in cardiomyocyte hypertrophy, ventricular dysfunction, and cardiac fibrosis. 19-22 Elevated IL-18 levels are observed in patients with HF and correlate with disease severity, but whether this inflammatory response is a cause or a consequence of the pathogenesis of HF is unknown.<sup>23</sup> Some, but not all, prospective cohort studies have reported that IL-18 is associated with incident coronary events<sup>24-26</sup> and HF, <sup>24, 27</sup> but not incident stroke.<sup>24</sup> It remains uncertain whether pharmacological inhibition of the IL-18 signaling pathway is a viable treatment option for a variety of cardiovascular diseases, including coronary disease, stroke, AF, and HF. In the absence of RCTs of therapeutics targeting the IL-18 signaling pathway for the treatment of cardiovascular disease, genetic studies can offer valuable insights into the ontarget effect of these pharmacological agents. <sup>28, 29</sup> Drug-target Mendelian Randomization (MR) employs genetic variants associated with the levels or activity of drug-target proteins, thus serving as proxies for pharmacological agents. <sup>28</sup> The primary aim of this study is to explore the potential benefit of IL-18 inhibition on cardiovascular outcomes using a drugtarget MR approach. Methods Study design We used MR to assess the causal association between genetically proxied downregulation of IL-18 signaling and: 1) cardiovascular disease outcomes, with replication in non-overlapping samples where possible; 2) cardiometabolic and inflammatory traits, including cardiac magnetic resonance (CMR) measures of cardiac structure and function; and 3) potential adverse and beneficial effects associated with reduced IL-18 signaling. An overview of the study design is detailed in Figure 1.

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

Initially, we examined the validity of our genetic instrument as a pharmacological proxy for downregulated IL-18 signaling by assessing its impact on established downstream biomarkers: IL-6, C-reactive protein (CRP), interferon-gamma (IFN-γ), and tumor necrosis factor. These biomarkers were identified from pre-clinical<sup>30</sup> and early-phase clinical studies of therapies targeting the IL-18 signaling pathway.<sup>31, 32</sup> Circulating levels of IL-1β were selected as a negative control because as IL-1 $\beta$  functions through an alternative signaling pathway, its levels are not expected to be affected by IL-18 signaling. Two-sample cis-MR was then used to elucidate the relationship between on-target reduced IL-18 signaling and the risk of cardiovascular disease. Subsequent analyses assessed the bidirectional effects between liability to diseases identified in primary analyses and circulating IL-18 levels. We undertook a mediation analysis to identify pathways that contribute to the effect of genetically predicted IL-18 blockade on cardio-embolic stroke. Finally, we explored the effect of downregulated IL-18 signaling on longevity and a selection of clinically relevant outcomes to identify potential adverse outcomes associated with an impaired host immune response. We used parental age at death, a partially heritable trait, as an indirect measure of longevity.<sup>33</sup> **Data Sources** For our primary CVD outcomes, we obtained summary statistics for stroke from GIGASTROKE (N<sub>cases</sub> = 62,100), peripheral arterial disease from the GoLEAD and Summit Consortium (N<sub>cases</sub> = 12,086), coronary artery disease from CARDIoGRAMplusC4D (N<sub>cases</sub> = 181,522), HF from Aragram et al's GWAS of ischaemic and non-ischaemic HF in the UK Biobank (UKB) (N<sub>cases</sub> = 6,504), dilated cardiomyopathy from Ning et al.'s GWAS in UKB  $(N_{cases} = 1,303)$  and AF from Nielsen's genome-wide association meta-analysis with UKB excluded ( $N_{cases} = 45,800$ ). Summary statistics for lipid traits were derived from the Global Lipids Genetics Consortium (N = 1,320,016) and a UKB GWAS conducted by Richardson et

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

al (N = 115,082). For inflammatory markers, summary statistics were sourced as follows: CRP from Said et al.'s GWAS involving over 500,000 individuals; tumor necrosis factor from The INTERVAL Study (N = 3,301); interferon-gamma from Ahola-Olli et al.'s GWAS (N =7,701); IL-1 beta from deCODE (N = 35,559); CXCL10 from Gudjonsson et al.'s GWAS (N = 5,366), and IL-6 from a genome-wide meta-analysis by Zhao et al (N = 14,743). Summary statistics for cardiac magnetic resonance (CMR) imaging traits were sourced from four GWAS in UKB ( $N_{range} = 16,920-41,505$ ). Detailed information on all data sources used in this study is available in the Supplementary Methods or Supplementary Table 1. Instrumental variable selection Summary statistics for circulating IL-18 concentration were obtained from the Scallop Consortium's genome-wide association meta-analysis of 90 Olink-measured proteins from 13 contributing cohorts containing 21,758 European individuals.<sup>34</sup> We identified common (minor allele frequency >0.01) cis-genetic variants associated with circulating IL-18 concentration at genome-wide significance from within a 100kb flanking region of the IL-18 gene (hg19: chromosome 11: 112013974-112034840). Variants were then clumped using a linkage disequilibrium (LD) threshold r<sup>2</sup><0.1 and a distance threshold of 100kb, utilizing data from the 1000 Genomes Project European reference panel. This methodology selected five partially correlated cis-variants with the strongest association with circulating IL-18 concentration within each LD region from around the IL-18 gene, as described in Supplementary Table 2. Instrument strength was assessed through the calculation of an Fstatistic and a mean F-statistic >10 was considered strong. For bidirectional MR analyses, we created instruments for each cardiometabolic disease by selecting genetic variants associated with each outcome at genome-wide significance from throughout the genome. We clumped these variants using an LD threshold of r<sup>2</sup> < 0.001 and a distance threshold of 10,000 kb. We

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

relaxed our significance threshold for HF to  $5 \times 10^{-7}$  due to a scarcity of genome-wide significant variants. **Statistical analysis** Mendelian randomization analyses Causal estimates from MR analyses rely on three key assumptions: (i) relevance, where the genetic instrument must be associated with the exposure; (ii) independence, where the instrument is not associated with any confounders of the exposure-outcome relationship; and (iii) exclusion restriction, where the instrument affects the outcome solely through its effect on the exposure.<sup>35</sup> Random-effects inverse-variance weighted (IVW) models were used in primary MR analyses. For all significant associations, we conducted a range of sensitivity analyses to assess for possible violations of the underlying assumptions of MR, including weighted median and mode to assess for consistency of results, MR Egger to assess for directional pleiotropy and MR PRESSO to adjust for the effect of potential outliers.<sup>35</sup> We repeated all analyses using generalized inverse variance weighted MR, which adjusts for residual pairwise LD among variants included in our IL-18 instrument.<sup>35</sup> **Mediation** analysis Following the methodology described by Woolf et al., we employed two-step cis-MR to calculate the proportion of the effect of downregulated IL-18 signaling on cardio-embolic stroke that was mediated by downstream cardiometabolic traits identified in primary analyses. 36 This involved estimating the effect of IL-18 on each potential mediator, followed by assessing the impact of each mediator on the outcome while adjusting for IL-18. We then calculated the proportion of IL-18's overall effect on cardioembolic stroke mediated by each outcome by dividing the indirect effect by the total effect. We used the weighted median

estimator for the mediation analysis if heterogeneity was detected in the inverse-variance weighted MR estimate. Standard errors and the 95% CI for the proportion mediated were calculated using the delta method.<sup>37</sup>

## Colocalization and LD check

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

Bayesian colocalization was used to determine if levels of circulating IL-18 and our primary outcomes share a single causal variant at the IL-18 gene locus, which may indicate a causal pathway between the exposure and the outcome.<sup>38</sup> Colocalization involves calculating posterior probabilities (PP) for five hypotheses to assess the likelihood that the genetic variants influencing two traits at a specific locus are overlapping or distinct. H0 suggests that there is no genetic association with either trait; H1 and H2 suggest that only the first or second trait has a genetic association; H3 suggests that both traits are associated but have different causal variants; and H4 suggests that both traits are associated and share a single causal variant. Colocalization analyses rely on a well-powered outcome GWAS and sufficient variant coverage in the region of interest.<sup>38, 39</sup> A posterior probability (PP) for H3 (distinct causal variant) and H4 (shared causal variant) less than 0.8, in the context of a statistically significant MR association, may signal an underpowered outcome GWAS to determine if the association is due to a shared causal variant or from a confounding variant in LD (i.e. horizontal pleiotropy). LD Check is an alternative method for co-localization when variant coverage is insufficient for Bayesian colocalization. <sup>39</sup> LD Check estimates the LD between the sentinel IL-18 variant and the top 30 variants from the same genomic region in each outcome study. Causality with the sentinel IL-18 variant is suggested if at least one of the top 30 SNPs exhibits strong LD  $(r^2 > 0.8)$ .

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

Reporting and packages Results from MR analyses are reported as odds ratios (OR) for binary outcomes and standard deviation (SD) difference for continuous outcomes per SD lower in genetically predicted IL-18 levels. Results from bidirectional MR analyses are reported as the effect of a one-unit increase in the log odds of genetic liability for each cardiometabolic disease. We applied the Benjamini-Hochberg method to control for the false discovery rate (FDR) across all phenotypes and report the unadjusted and FDR-adjusted p-values. Associations with a nominal p-value <0.05 and a Benjamini-Hochberg adjusted p-value >0.05 were deemed suggestive. Associations with a Benjamini-Hochberg adjusted p-value <0.05 were considered significant. Analyses were performed in R (v4.2.1; R Foundation for Statistical Computing) with the TwoSampleMR, MendelianRandomisation, Coloc and TwoStepCisMR packages. Standard Protocol Approvals, Registrations, and Patient Consents All contributing studies obtained appropriate informed consent from participants and received ethical approval before commencement. This study was conducted in adherence to the guidelines for Strengthening the Reporting of Observational Studies in Epidemiology – Mendelian randomization (STROBE- MR), as detailed in the Supplement. Data availability This study utilizes publicly available, summary-level GWAS data that can be accessed through the GWAS Catalogue (https://www.ebi.ac.uk/gwas/home) and the Integrative Epidemiology Unit (IEU) OpenGWAS project (https://gwas.mrcieu.ac.uk/) or specific cohort portals, including The Scallop Consortium (https://zenodo.org/records/2615265), The Centre for Statistical Genetics (<a href="https://csg.sph.umich.edu/willer/public/afib2018/">https://csg.sph.umich.edu/willer/public/afib2018/</a>), Pan-UK Biobank (https://pan.ukbb.broadinstitute.org/), The Human Genetics Amplifier (HuGeAMP)

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

(https://kp4cd.org/node/169), The Usher Institute of Population Health Sciences and Informatics (https://datashare.ed.ac.uk/handle/10283/3209), The Cardiovascular Disease Knowledge Portal (https://cvd.hugeamp.org/downloads.html), The NBDC Human Database (https://humandbs.dbcls.jp/en/), The Complex Trait Genetics Lab (https://cncr.nl/research/summary statistics/) and FinnGen (https://www.finngen.fi/en/access results). **Results** Genetically downregulated IL-18 signaling and cardiometabolic biomarkers Our instrument for lower genetically downregulated IL-18 signaling, composed of 5 variants, had a mean F-statistic of 124, indicating an appropriate average instrument strength, and explained 3.64% of the total variation of circulating IL-18 levels in the Scallop Consortium. Lower genetically predicted IL-18 levels were associated with several downstream biomarkers of IL-18 signaling, suggesting that our instruments represented a proxy for IL-18 signaling downregulation. The downstream biomarkers that were significantly associated with genetically proxied IL-18 levels included C-reactive protein (CRP) (SD change -0.02, 95% CI -0.03, -0.02, p<sub>fdr</sub><0.001), tumor necrosis factor (SD change -0.19, 95% CI -0.25, -0.14, p<sub>fdr</sub> <0.001), interferon-gamma (IFN-y) (SD change -0.15, 95% CI -0.22, -0.08, p<sub>fdr</sub> <0.001) and CXCL10 (SD change -0.13, 95% CI -0.16, -0.09, p<sub>fdr</sub> <0.001), but not IL-1β or IL-6 (Figure 2). Lower genetically predicted IL-18 levels were associated with higher diastolic blood pressure (SD change 0.02, 95% CI 0.02, 0.03, p<sub>fdr</sub> =<0.001) and body mass index (SD change 0.02, 95% CI 0.02, 0.01, p<sub>fdr</sub>=0.017), but had no association with lipid subfractions.

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

Genetically downregulated IL-18 signaling and cardiometabolic diseases Lower genetically predicted IL-18 levels (1 SD decrease in IL-18 levels) were associated with 15% lower odds of cardio-embolic stroke (OR 0.85, 95% CI 0.79-0.92,  $p_{fdr}$ <0.001, Figure 3) and 9% lower odds of peripheral arterial disease (OR 0.91, 95% CI 0.84-0.97, p<sub>fdr</sub> =0.027), but had no association with other stroke subtypes, coronary artery disease or aortic stenosis. In UKB, lower genetically predicted IL-18 levels were also associated with reduced odds of both all-cause HF (OR 0.83, 95% CI 0.75-0.91, p<sub>fdr</sub><0.001) and dilated cardiomyopathy (OR 0.74, 95% CI 0.58-0.93, p<sub>fdr</sub>=0.031). When assessing related cardiometabolic diseases, lower genetically predicted IL-18 levels were associated with lower odds of chronic kidney disease (CKD) (OR 0.91, 95% CI 0.84-0.99, p<sub>fdr</sub>=0.027), and type 2 diabetes mellitus (T2DM) (OR 0.97, 95% CI 0.95-0.99,  $p_{fdr} = 0.027$ ). Additionally, there was a trend towards an association between lower genetically predicted IL-18 levels and reduced risk of AF (OR 0.94, 95% CI 0.89-0.99,  $p_{fdr} = 0.054$ ), which did not maintain significance following false discovery rate adjustment. Associations for HF were successfully replicated in a non-overlapping sample of American cohort studies (OR 0.85, 95% CI 0.75-0.95, p =0.004, Supplementary Table 3). For AF, results were directionally similar but did not reach statistical significance in the UK Biobank (UKB) (OR 0.96, 95% CI 0.92-1.00, p = 0.061). In colocalization analyses between IL-18 and AF, peripheral arterial disease, HF, cardioembolic stroke, CKD and T2DM, the posterior probabilities of H3 and H4 were less than 0.8 and this along with the low minimum p-values in the IL-18 gene region in each of the outcome summary statistics implies suboptimal power for colocalization, the presence of confounding by LD or multiple causal variants within the gene region. We subsequently conducted an LD Check analysis and obtained the LD correlation between the sentinel

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

variant (rs5744249) from the *IL-18* gene locus and the top 30 variants within 100kb of rs5744249 with the lowest p-values from the cardio-embolic stroke, AF, peripheral arterial disease, HF, CKD and T2DM summary statistics. At least one top cis-variant from each outcome dataset, except for peripheral arterial disease, exhibited strong LD ( $r^2 > 0.8$ ) with the sentinel variant. This suggests potential causal associations between IL-18 and cardioembolic stroke, AF, HF, CKD and T2DM Genetically downregulated IL-18 signaling and cardiac magnetic resonance imaging traits In UKB, there were directionally consistent improvements in all measures of cardiac structure and function with lower genetically predicted IL-18 levels as displayed in Figure 3, with the exception of left and right ventricular ejection fractions. Following adjustment for multiple testing, lower genetically predicted IL-18 levels were associated with a reduction in left atrial size (SD change -0.02, 95% CI -0.03, -0.00,  $p_{fdr} = 0.022$ ) and left ventricular endsystolic volume (SD change -0.08, 95% CI -0.13, -0.02,  $p_{fdr} = 0.039$ ). Genetically downregulated IL-18 signaling and potential adverse effects Lower genetically predicted IL-18 levels were associated with a longer parental lifespan, an indirect measure of longevity (SD change 0.02 years, 95% CI 0.01-0.04,  $p_{fdr} = 0.005$ ), and reduced risk of a range of autoimmune diseases, including atopic dermatitis (OR 0.86, 95% CI 0.83-0.90, p<sub>fdr</sub> <0.001), psoriasis (OR 0.84-0.89, p<sub>fdr</sub> <0.001), asthma (OR 0.90, 95% CI 0.86-0.94,  $p_{fdr} < 0.001$ ), and rheumatoid arthritis (OR 0.85, 95% CI 0.81-0.90,  $p_{fdr} < 0.001$ , Figure 4). There was also a trend toward an association between lower genetically predicted IL-18 levels and reduced risk of ulcerative colitis (OR 0.88, 95% CI 0.79-0.98,  $p_{fdr} = 0.051$ ), which did not maintain significance following false discovery rate adjustment. While lower

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

genetically predicted IL-18 levels were not significantly associated with an increased risk of infection, it was associated with higher odds of lung cancer (OR 1.15, 95% CI 1.11-1.20, p<sub>fdr</sub> <0.001) and multiple sclerosis (OR 1.17, 95% CI 1.03-1.32, p<sub>fdr</sub> = 0.041). Bidirectional relationship between cardiometabolic diseases and IL-18 levels In reverse MR analyses, genetic liability to cardio-embolic stroke was not significantly associated with circulating levels of IL-18 (β representing the effect of one unit increase in the log odds of genetic liability for cardioembolic stroke -0.03, 95% CI -0.08-0.02, p = 0.267). Similarly, circulating levels of IL-18 were not affected by genetic liability to AF (\beta 0.00, 95% CI -0.03-0.04, p  $0.879), HF (<math>\beta$  -0.03, 95% CI -0.22-0.16, p  $=0.743), CKD (<math>\beta$  0.01, p95% CI -0.07-0.06, p = 0.821), peripheral arterial disease ( $\beta$  0.07, 96% CI -0.26-0.39, p = 0.686), or higher BMI ( $\beta$  0.05, 95% CI -0.01-0.12, p = 0.104). **Mediation analyses** We performed two-step network MR mediation analyses to quantify the extent to which downstream cardiometabolic traits mediate the relationship between IL-18 signaling and cardio-embolic stroke. We observed that genetic liability to AF accounted for 25% of the total effect of lower genetically predicted IL-18 levels on cardio-embolic stroke (proportionmediated 25.1%, 95% CI 22.4-27.8%, p < 0.001, Supplementary Table 4). Genetic liability to all-cause HF accounted for 5.6% of the total effect (proportion-mediated 5.3%, 95% CI 1.7-8.8%, p =0.003), while genetic liability to CKD mediated 2.8% of the total effect of downregulated IL-18 signaling on cardio-embolic stroke (proportion-mediated 2.8%, 95% CI 0.1-5.7%, p =0.054). However, BMI had a more modest impact, mediating 1.61% of the total effect (proportion-mediated 1.6%, 95% CI -2.0-5.2%, p =0.383), while

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

genetic liability to T2DM had little impact, mediating only 0.8% of the total effect of lower genetically predicted IL-18 levels on cardio-embolic stroke (proportion-mediated 0.8%, 95% CI - 2.8 - 4.4%, p = 0.657 Sensitivity analyses The MR estimates from generalized IVW, weighted median, weighted mode, MR Egger, and MR PRESSO are reported in Supplementary Tables 5.1-5.24. No heterogeneity was observed across all MR analyses, as indicated by Cochrane's O and Rucker's O statistics. Estimates were consistent with primary results when using generalized IVW MR to model residual LD, and directionally similar across weighted median and weighted mode methods. The p-values for the MR Egger intercept test and the global MR PRESSO test were not significant, suggesting an absence of marked pleiotropy. **Discussion** Leveraging data from large-scale genomic, proteomic and imaging studies, we have demonstrated new and important evidence linking IL-18 signaling to HF, peripheral arterial disease, atrial cardiomyopathy, and cardio-embolic stroke. Lower genetically predicted IL-18 levels were associated with reduced concentrations of several downstream inflammatory cytokines and exhibited protective effects on cardiac structure and function. Genetic liability to AF and HF mediated a significant proportion of the risk-lowering effect of IL-18 signaling on cardioembolic stroke. Lower genetically predicted IL-18 levels were associated with a favorable metabolic profile overall, with a lower risk of T2DM, CKD, autoimmune disease, and enhanced longevity.

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

The present data are supported by several lines of evidence from experimental models, observational studies, and emerging data from RCTs implicating the NLRP3-inflammasome and IL-18 activation in HF and AF. The NLRP3-inflammasome is activated by proinflammatory mediators, such as IL-1β and TNF-alpha, damage-associated molecular patterns (DAMPs) secondary to ischemia-reperfusion injury, and angiotensin II overexpression from renin-angiotensin activation. 4, 21, 40 IL-18 activation ensues secondary to NLRP3 inflammasome formation in leukocytes, endothelial cells, fibroblasts, and cardiomyocytes. <sup>21</sup> The binding of IL-18 to its receptor triggers the recruitment of tumor necrosis factor receptor-associated factor-6 (TRAF6), and the activation of nuclear factor Kappa B (NF-κB) and p38 mitogen-activated protein kinase (MAPK). <sup>21</sup> This cascade results in the synthesis of secondary inflammatory mediators, including IFN- $\gamma$  and TNF- $\alpha$ . <sup>30</sup> In-vitro and animal models have demonstrated that disrupting the IL-18 signaling pathway can reduce myocardial hypertrophy, improve contractile function, and decrease fibrosis. <sup>21, 22</sup> IL-18 mediates β-adrenergic receptor stimulation-induced macrophage infiltration, cardiac inflammation, and fibrosis. <sup>20</sup> IL-18 also triggers apoptosis in microvascular endothelial cells through activation of NF-kB and upregulates the expression of osteopontin, fibronectin, and matrix metalloproteinase 2 (MMP-2) in human cardiac fibroblasts. <sup>21</sup> In humans, IL-18 levels increase in proportion to disease progression in both HF<sup>23</sup> and AF.<sup>41, 42</sup> In the Atherosclerosis Risk in Communities (ARIC) study circulating IL-18 in mid-life was associated with future risk of HF.<sup>24</sup> Similarly, Henry et al.'s meta-analysis of four population-based studies demonstrated an association between IL-18 levels and risk of incident HF.<sup>27</sup> Our results suggest that the IL-18 signaling pathway is a viable treatment target in AF, HF and cardio-embolic stroke. Our data were derived from non-overlapping cohorts and demonstrated biologically consistent results, implicating IL-18 at the center of multiple

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

downstream pro-inflammatory pathways, cardiac remodeling, AF, HF, and ultimately cardioembolic stroke. Our two-step cis-MR analysis suggests that the reduced risk of cardioembolic stroke associated with downregulated IL-18 signaling is likely mediated through its protective effects against lifetime cardiac remodeling, cardiomyopathy, and AF. Our results are supported by Schmidt et al.'s recent cis-MR study which showed that targeting the IL-18 receptor is associated with four left ventricular CMR traits and risk of dilated cardiomyopathy. 43 Furthermore, in their candidate gene study, Wang et al. demonstrated that three variants associated with IL18 gene expression increased risk of AF and left atrial enlargement.44 The global burden of stroke, HF and AF is increasing. 45, 46 There is a pressing need to identify and develop disease-modifying therapies that prevent stroke and slow disease progression in both HF and atrial cardiopathy. In atherosclerosis, colchicine and canakuinumab have both shown benefit in reducing major adverse cardiovascular events (MACE) in coronary artery disease.<sup>1,2</sup> Although colchicine did not reduce the risk of MACE after non-cardioembolic stroke, a 20% reduced risk was observed in an on-treatment analysis suggesting a possible biological effect.<sup>3</sup> Apart from the treatment of atherosclerosis, there is also increasing interest in targeting inflammation in HF and AF. Whilst there is some evidence that colchicine reduces the risk of postoperative AF following cardiac surgery and decreases AF recurrence after pulmonary vein isolation or ablation<sup>47</sup>, a recent RCT was neutral.<sup>12</sup> Currently, no licensed anti-inflammatory therapies have been proven to prevent hard outcomes in HF. RCTs investigating the potential of TNFα inhibition were neutral. <sup>10, 11</sup> Anakinra, an anti-IL-1 monoclonal antibody, improved several surrogate markers of cardiac function but failed to significantly reduce hospitalization for HF or death. 48 While genetic studies have identified the IL-6 signaling pathway as a potential druggable target for AF, they do not support a

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

causal role in HF or cardio-embolic stroke. 16 Consequently, future experimental work and RCTs should now focus on the potential benefit of IL-18 pathway suppression in the treatment of HF and the prevention of cardio-embolic stroke. Our results suggest that IL-18 inhibition would likely have a favourable cardio-metabolic profile. Downregulated IL-18 signaling reduced risk of CKD and T2DM, which are key risk factors for cardiovascular disease. However, we did observe that IL-18 suppression was associated with marginal increases in diastolic blood pressure and BMI while having minimal effect on lipid fractions and systolic blood pressure. The clinical relevance of these findings will need to be explored in future studies. We show that downregulated IL-18 signaling is associated with lower risk of atopic disease, which supports the rationale for ongoing clinical trials of IL-18 signaling-blocking therapies in atopic dermatitis. Promising agents for potential repurposing in cardiovascular disease include GSK1070806 and Camoteskimab, which are human monoclonal antibodies targeting IL-18, as well as tadekinig  $\alpha$ , a recombinant human IL-18 binding protein that sequesters IL-18. Immunomodulatory therapies carry potential risks, notably with respect to host response to infections and malignancy. Our study shows that downregulated IL-18 signaling increases the risk of lung cancer, but not other cancers or infection. Most importantly, we show that reduced IL-18 signaling is associated with enhanced lifespan, indicative of a net positive effect on all-cause mortality. Previous data from experimental models and some epidemiological studies suggested that IL-18 was associated with atherosclerosis and coronary disease. 26, 49 Apart from a modest association with peripheral arterial disease that did not have LD Check support, we did not find any compelling evidence that IL-18 signaling is causally associated with atherosclerotic

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

endpoints. On the contrary, prior MR studies have implicated IL-6 signaling in coronary artery disease and atherosclerotic stroke. 16 Together with data from CANTOS suggesting the potential benefit of IL-1β-IL-6 axis suppression,<sup>2</sup> our analysis supports the rationale of ongoing trials focusing on the high potential of IL-6 pathway inhibition in atherosclerosis.<sup>17</sup> Our study has several strengths. The MR study design minimizes bias from reverse causation and environmental confounders, while cis-MR provides an evaluation of the effects of directly perturbing a drug target on disease outcomes. We leveraged large multi-omic datasets to uncover new insights into how downregulated IL-18 signaling influences cardiovascular disease. Moreover, we developed a robust genetic cis-instrument that mirrors the effects of reduced IL-18 signaling on downstream biomarkers and conducted a comprehensive set of mediation and sensitivity analyses to improve confidence in our findings. We were also able to validate our findings for HF in independent cohorts. We acknowledge some limitations. Although we utilized large genomic consortia for outcome summary statistics, our analyses may have been underpowered to detect associations with rarer phenotypes. Effect sizes derived from drug-target MR studies reflect lifelong perturbation of the drug target rather than the short-term treatment durations typically seen in clinical practice, potentially leading to significant differences in the observed benefits. Twosample MR methods assume a linear relationship between genetically proxied exposures and outcomes. In cases of non-linearity, the MR estimates reflect a population average effect rather than capturing potentially varying effects across different levels of exposure. Similarly, in clinical practice, the biological response to drugs often requires surpassing a specific therapeutic dose, a detail that two-sample MR studies might not capture due to their reliance on average effects. Two-step cis-MR relies on several assumptions including linearity, and may yield unreliable estimates when the mediator or outcome is not continuous, potentially

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

impacting the accuracy of our effect size estimates and the interpretation of IL-18 signaling mediation on cardio-embolic stroke through AF, HF, CKD, and T2DM. Our analyses were limited to individuals of European ancestry to minimize confounding by population stratification and the potential impact of downregulated IL-18 signaling on risk of cardiovascular disease in non-European ancestries remains to be explored. Finally, our MR estimates reflect the impact of downregulated IL-18 signaling on incident disease, and it remains unclear how appliable these findings are to individuals with established disease, who are more likely to be prioritized for treatment and inclusion in clinical trials. In conclusion, this study used large-scale multi-omic data to explore the effects of genetically downregulated IL-18 signaling on cardiovascular disease. We provide compelling data which suggests the IL-18 pathway is causally implicated in the evolution of cardiomyopathy, from structural remodelling through to an increased risk of HF and cardio-embolic stroke. These data strongly suggest that IL-18 represents a viable target for the prevention and treatment of stroke and heart failure, with a favorable cardiometabolic and autoimmune profile, that warrants further exploration in clinical trials. **Sources of funding** PJK has received funding from the Irish Health Research Board. DG is supported by the British Heart Foundation Centre of Research Excellence (RE/18/4/34215) at Imperial College London. **Disclosures** The authors have no relevant conflicts of interest to disclose.

#### References

577

- 578 1. Xia M, Yang X, Qian C. Meta-analysis evaluating the utility of colchicine in secondary prevention of coronary artery disease. *Am J Cardiol*. 2021;140:33-38
- 580 2. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al.
- Antiinflammatory therapy with canakinumab for atherosclerotic disease. *New England Journal of Medicine*. 2017;377:1119-1131
- 583 3. Kelly P, Lemmens R, Weimar C, Walsh C, Purroy F, Barber M, et al. Long-term 584 colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke 585 (convince): A randomised controlled trial. *The Lancet*. 2024
- 586 4. Yao C, Veleva T, Scott L, Cao S, Li L, Chen G, et al. Enhanced cardiomyocyte nlrp3 587 inflammasome signaling promotes atrial fibrillation. *Circulation (New York, N.Y.)*. 588 2018;138:2227-2242
- 589 5. McKechnie DGJ, Papacosta AO, Lennon LT, Welsh P, Whincup PH, Wannamethee SG. Inflammatory markers and incident heart failure in older men: The role of nt-probnp. *Biomarkers in Medicine*. 2021;15:413-425
- 592 6. Szabo TM, Frigy A, Nagy EE. Targeting mediators of inflammation in heart failure: A short synthesis of experimental and clinical results. *Int J Mol Sci.* 2021;22
- Conen D, Ridker PM, Everett BM, Tedrow UB, Rose L, Cook NR, et al. A
   multimarker approach to assess the influence of inflammation on the incidence of
   atrial fibrillation in women. *Eur Heart J.* 2010;31:1730-1736
- Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal
   RA, et al. Inflammation as a risk factor for atrial fibrillation. *Circulation*.
   2003;108:3006-3010
- 600 9. Aulin J, Siegbahn A, Hijazi Z, Ezekowitz MD, Andersson U, Connolly SJ, et al.
  601 Interleukin-6 and c-reactive protein and risk for death and cardiovascular events in
  602 patients with atrial fibrillation. *Am Heart J*. 2015;170:1151-1160
- Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, et al.
  Targeted anticytokine therapy in patients with chronic heart failure: Results of the
  randomized etanercept worldwide evaluation (renewal). *Circulation*. 2004;109:15941602
- Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: Results of the anti-tnf therapy against congestive heart failure (attach) trial. *Circulation*. 2003;107:3133-3140
- Benz AP, Amit G, Connolly SJ, Singh J, Acosta-Vélez JG, Conen D, et al. Colchicine to prevent atrial fibrillation recurrence after catheter ablation: A randomized, placebocontrolled trial. *Circulation: Arrhythmia and Electrophysiology*. 2024;17:e01238
- Abbate A, Toldo S, Marchetti C, Kron J, Van Tassell BW, Dinarello CA. Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease. *Circulation* research. 2020;126:1260-1280
- 618 14. Kaptoge S, Seshasai SR, Gao P, Freitag DF, Butterworth AS, Borglykke A, et al.
  619 Inflammatory cytokines and risk of coronary heart disease: New prospective study
  620 and updated meta-analysis. *Eur Heart J.* 2014;35:578-589
- Papadopoulos A, Palaiopanos K, Bjorkbacka H, Peters A, de Lemos JA, Seshadri S, et al. Circulating interleukin-6 levels and incident ischemic stroke: A systematic review and meta-analysis of prospective studies. *Neurology*. 2021

- 624 16. Georgakis MK, Malik R, Gill D, Franceschini N, Sudlow CLM, Dichgans M, et al.
  625 Interleukin-6 signaling effects on ischemic stroke and other cardiovascular outcomes:
  626 A mendelian randomization study. *Circ Genom Precis Med.* 2020;13:e002872
- Ridker PM, Rane M. Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease. *Circ Res.* 2021;128:1728-1746
- 629 18. McCabe JJ, Walsh C, Gorey S, Harris K, Hervella P, Iglesias-Rey R, et al. C-reactive 630 protein, interleukin-6, and vascular recurrence after stroke: An individual participant 631 data meta-analysis. *Stroke*. 2023
- Toldo S, Mezzaroma E, O'Brien L, Marchetti C, Seropian IM, Voelkel NF, et al.
   Interleukin-18 mediates interleukin-1-induced cardiac dysfunction. *Am J Physiol Heart Circ Physiol*. 2014;306:H1025-1031
- Xiao H, Li H, Wang J-J, Zhang J-S, Shen J, An X-B, et al. II-18 cleavage triggers
   cardiac inflammation and fibrosis upon β-adrenergic insult. *European Heart Journal*.
   2017;39:60-69
- O'Brien LC, Mezzaroma E, Van Tassell BW, Marchetti C, Carbone S, Abbate A, et al.
   Interleukin-18 as a therapeutic target in acute myocardial infarction and heart failure.
   Mol Med. 2014;20:221-229
- Yu Q, Vazquez R, Khojeini EV, Patel C, Venkataramani R, Larson DF. II-18 induction of osteopontin mediates cardiac fibrosis and diastolic dysfunction in mice. *Am J Physiol Heart Circ Physiol*. 2009;297:H76-85
- Yamaoka-Tojo M, Tojo T, Inomata T, Machida Y, Osada K, Izumi T. Circulating levels
   of interleukin 18 reflect etiologies of heart failure: Th1/th2 cytokine imbalance
   exaggerates the pathophysiology of advanced heart failure. *J Card Fail*. 2002;8:21-27
- Jia X, Buckley L, Sun C, Al Rifai M, Yu B, Nambi V, et al. Association of interleukin-648
   6 and interleukin-18 with cardiovascular disease in older adults: Atherosclerosis risk in communities study. *European Journal of Preventive Cardiology*. 2023;30:1731-1740
- Kaptoge S, Seshasai SRK, Gao P, Freitag DF, Butterworth AS, Borglykke A, et al.
   Inflammatory cytokines and risk of coronary heart disease: New prospective study
   and updated meta-analysis. *European Heart Journal*. 2013;35:578-589
- Jefferis BJ, Papacosta O, Owen CG, Wannamethee SG, Humphries SE, Woodward M,
   et al. Interleukin 18 and coronary heart disease: Prospective study and systematic
   review. Atherosclerosis. 2011;217:227-233
- 657 27. Henry A, Gordillo-Marañón M, Finan C, Schmidt AF, Ferreira JP, Karra R, et al.
  658 Therapeutic targets for heart failure identified using proteomics and mendelian
  659 randomization. *Circulation*. 2022;145:1205-1217
- 660 28. Gill D, Georgakis M, Walker V, Schmidt A, Gkatzionis A, Freitag D, et al. Mendelian randomization for studying the effects of perturbing drug targets [version 2; peer review: 3 approved, 1 approved with reservations]. *Wellcome Open Research*. 2021;6
- 663 29. Minikel EV, Painter JL, Dong CC, Nelson MR. Refining the impact of genetic evidence on clinical success. *Nature*. 2024;629:624-629
- 665 30. Kaplanski G. Interleukin-18: Biological properties and role in disease pathogenesis. 666 *Immunological reviews*. 2018;281:138-153
- Gabay C, Fautrel B, Rech J, Spertini F, Feist E, Kötter I, et al. Open-label, multicentre, dose-escalating phase ii clinical trial on the safety and efficacy of tadekinig alfa (il-18bp) in adult-onset still's disease. *Annals of the Rheumatic Diseases*. 2018;77:840-847
- Robertson MJ, Kirkwood JM, Logan TF, Koch KM, Kathman S, Kirby LC, et al. A dose-escalation study of recombinant human interleukin-18 using two different

- schedules of administration in patients with cancer. *Clinical Cancer Research*. 2008;14:3462-3469
- 675 33. Pilling LC, Atkins JL, Bowman K, Jones SE, Tyrrell J, Beaumont RN, et al. Human longevity is influenced by many genetic variants: Evidence from 75,000 uk biobank participants. *Aging (Albany NY)*. 2016;8:547
- Folkersen L, Gustafsson S, Wang Q, Hansen DH, Hedman ÅK, Schork A, et al.
   Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals. *Nature metabolism*. 2020;2:1135-1148
- 681 35. Richmond RC, Smith GD. Mendelian randomization: Concepts and scope. *Cold Spring Harbor perspectives in medicine*. 2022;12:a040501
- Woolf B, Zagkos L, Gill D. Twostepcismr: A novel method and r package for attenuating bias in cis-mendelian randomization analyses. *Genes.* 2022;13:1541
- Tofighi D, MacKinnon DP. Rmediation: An r package for mediation analysis confidence intervals. *Behavior research methods*. 2011;43:692-700
- Zuber V, Grinberg NF, Gill D, Manipur I, Slob EA, Patel A, et al. Combining
   evidence from mendelian randomization and colocalization: Review and comparison
   of approaches. *The American Journal of Human Genetics*. 2022;109:767-782
- Zheng J, Haberland V, Baird D, Walker V, Haycock PC, Hurle MR, et al. Phenomewide mendelian randomization mapping the influence of the plasma proteome on complex diseases. *Nature genetics*. 2020;52:1122-1131
- 693 40. Mezzaroma E, Abbate A, Toldo S. The inflammasome in heart failure. *Curr Opin Physiol.* 2021;19:105-112
- Liu Y, Luo D, Liu E, Liu T, Xu G, Liang X, et al. Mirna21 and il-18 levels in left
   atrial blood in patients with atrial fibrillation undergoing cryoablation and their
   predictive value for recurrence of atrial fibrillation. *Journal of Interventional Cardiac Electrophysiology*. 2022;64:111-120
- Luan Y, Guo Y, Li S, Yu B, Zhu S, Li S, et al. Interleukin-18 among atrial fibrillation patients in the absence of structural heart disease. *Europace*. 2010;12:1713-1718
- Schmidt AF, Bourfiss M, Alasiri A, Puyol-Anton E, Chopade S, van Vugt M, et al.
   Druggable proteins influencing cardiac structure and function: Implications for heart failure therapies and cancer cardiotoxicity. *Science advances*. 2023;9:eadd4984
- Wang Y-H, Fu L, Wang B, Li S-F, Sun Z, Luan Y. Genetic variants of interleukin-18
   are associated with reduced risk of atrial fibrillation in a population from northeast china. *Gene*. 2017;626:269-274
- Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GM, Coats AJ. Global burden
   of heart failure: A comprehensive and updated review of epidemiology.
   Cardiovascular research. 2022;118:3272-3287
- 710 46. Collaborators GBDS. Global, regional, and national burden of stroke, 1990-2016: A systematic analysis for the global burden of disease study 2016. *Lancet Neurol*. 2019;18:439-458
- 713 47. Kommu S, Arepally S. The effect of colchicine on atrial fibrillation: A systematic review and meta-analysis. *Cureus*. 2023;15
- Van Tassell BW, Canada J, Carbone S, Trankle C, Buckley L, Oddi Erdle C, et al.
   Interleukin-1 blockade in recently decompensated systolic heart failure: Results from redhart (recently decompensated heart failure anakinra response trial). *Circulation:* Heart Failure. 2017;10:e004373
- Wang J, Sun C, Gerdes N, Liu C, Liao M, Liu J, et al. Interleukin 18 function in atherosclerosis is mediated by the interleukin 18 receptor and the na-cl co-transporter.
   Nature Medicine. 2015;21:820-826

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744


745


746

747

Figure 1. Overview of the study design. Stage 1 includes a graphical depiction of the interleukin-18 signaling pathway and a Manhattan plot illustrating the genome-wide association study of circulating concentration of interleukin-18 in the Scallop consortium. The red line indicates the genome-wide significance threshold ( $5 \times 10^{-8}$ ). Figure 2. The association between genetically downregulated IL-18 signaling and cardiometabolic biomarkers Shown are the results derived from random-effects inverse-variance weighted Mendelian randomization analyses. OR indicates odds ratio; CI, confidence interval; SD, standard deviation; FDR, false discovery rate; CXCL10, C-X-C motif chemokine ligand 10. Figure 3. The association between genetically downregulated IL-18 signaling and cardiometabolic diseases. Shown are the results derived from random-effects inverse-variance weighted Mendelian randomization analyses. OR indicates odds ratio; CI, confidence interval; SD, standard deviation. Figure 4. The association between genetically downregulated IL-18 signaling and cardiac magnetic resonance imaging traits. Shown are the results derived from random-effects inverse-variance weighted Mendelian randomization analyses. OR indicates odds ratio; CI, confidence interval; SD, standard deviation. Figure 5. The association between genetically downregulated IL-18 signaling and oncological, autoimmune, neurological, and infectious diseases Shown are the results derived from random-effects inverse-variance weighted Mendelian randomization analyses. OR indicates odds ratio; CI, confidence interval; SD, standard deviation.

### **Instrument Selection** Neutralization PAMPs NK Activation DAMPs Th Activation M Activation IL-18Rα Inflammation 10 8 MyD88 IL1-R IRAK1/4 MyD88 TRAF6 IRAK1/4 TRAF6 MAPK IκB NF-ĸB IFNy ProInflammatory Circulating levels of IL-18 Cytokines NF-ĸB in the Scallop Consortium





Outcome	Beta (95% CI)	P-val	FDR P-val
C-reactive protein	-0.02 (-0.03, -0.02)	<0.001	<0.001
Tumur necrosis factor	-0.19 (-0.25, -0.14)	<0.001	<0.001
Interferon gamma ————	-0.15 (-0.22, -0.08)	<0.001	<0.001
Interleukin 6	-0.05 (-0.11, 0.02)	0.148	0.269
Interleukin–1 beta	0.00 (-0.02, 0.02)	0.888	0.934
CXCL10 ——	-0.13 (-0.16, -0.09)	<0.001	<0.001
Total LDL−C	0.01 (0.00, 0.01)	0.033	0.080
Total HDL-C	-0.00 (-0.01, 0.00)	0.519	0.692
Triglycerides	0.00 (0.00, 0.01)	0.048	0.103
Apolipoprotein B —	-0.00 (-0.03, 0.03)	0.963	0.963
Apolipoprotein A1 —■—	-0.02 (-0.04, -0.00)	0.047	0.103
Systolic blood pressure	0.01 (-0.01, 0.02)	0.452	0.630
Diastolic blood pressure	0.02 (0.02, 0.03)	<0.001	<0.001
Body mass index —■—	0.02 (0.01, 0.04)	0.004	0.017
HbA1c ■	-0.00 (-0.01, 0.00)	0.421	0.616
-0.25 -0.2 -0.15 -0.1 -0.05 0 0 Change per SD lower in IL-18 levels (95% CI)	ר .05	29	)

Outcome	OR (95% CI)	P-val	FDR P-val
Coronary artery disease	1.00 (0.97, 1.02)	0.737	0.850
Peripheral artery disease ——■—	0.91 (0.84, 0.97)	0.008	0.027
Aortic stenosis	1.01 (0.91, 1.11)	0.896	0.934
All–cause heart failure ——■——	0.83 (0.76, 0.91)	<0.001	<0.001
Non-ischaemic heart failure	0.75 (0.59, 0.95)	0.019	0.051
Dilated cardiomyopathy	0.74 (0.58, 0.93)	0.010	0.031
Large artery stroke	1.03 (0.89, 1.20)	0.649	0.795
Cardioembolic stroke —■—	0.85 (0.79, 0.92)	<0.001	<0.001
Small vessel stroke	1.08 (0.93, 1.25)	0.299	0.448
All ischaemic stroke	1.02 (0.99, 1.05)	0.222	0.350
Atrial fibrillation —	0.93 (0.88, 0.99)	0.022	0.054
Left bundle branch block	1.00 (0.91, 1.09)	0.954	0.963
Right bundle branch block	0.96 (0.80, 1.16)	0.702	0.826
Atrioventricular block	1.01 (0.91, 1.12)	0.868	0.934
Abdominal aortic aneurysm	1.00 (0.95, 1.05)	0.903	0.934
Chronic kidney disease —■—	0.91 (0.84, 0.97)	0.008	0.027
Type 2 diabetes mellitus	0.97 (0.95, 0.99)	0.008	0.027
0.60 0.70 0.80 0.90 1.0 Odds Ratio per SD lower in IL–18 leve	1.1 1.2 1.3 els (95% CI)		30

Outcome		Beta (95% CI)	P-val	FDR P-val
Left atrial volume	-	-0.02 (-0.03, -0.00)	0.005	0.022
Left ventricular end systolic volume		-0.08 (-0.13, -0.02)	0.013	0.039
Left ventricular end distolic volume		-0.04 (-0.08, 0.00)	0.052	0.108
Left ventricular ejection fraction		0.03 (-0.02, 0.08)	0.299	0.448
Right ventricular end systolic volume	-	-0.02 (-0.04, 0.00)	0.062	0.124
Right ventricular end diastolic volume	-	-0.02 (-0.05, 0.01)	0.153	0.269
Right ventricular ejection fraction		0.02 (-0.03, 0.06)	0.446	0.630
T1 myocardial fibrosis	-	-0.01 (-0.04, 0.01)	0.182	0.304
	-0.2 -0.15 -0.1 -0.05 0 0.05 0.1 Change per SD lower in IL-18 levels (95% CI)		31	

Outcome	OR (95% CI)	P-val	FDR P-val
Oncological			
Lung cancer ————	1.15 (1.11, 1.20)	<0.001	<0.001
Breast cancer	0.94 (0.87, 1.02)	0.131	0.249
Prostate cancer	1.02 (0.95, 1.09)	0.555	0.724
Colorectal cancer	1.05 (0.88, 1.27)	0.577	0.737
Autoimmune			
Atopic dermatitis ——	0.86 (0.83, 0.90)	<0.001	<0.001
Psoriasis ——	0.84 (0.80, 0.89)	<0.001	<0.001
Asthma ———	0.90 (0.86, 0.94)	<0.001	<0.001
Rheumatoid arthritis ——	0.85 (0.81, 0.90)	<0.001	<0.001
Ulcerative colitis —	0.88 (0.79, 0.98)	0.020	0.051
Crohn's disease	0.99 (0.85, 1.15)	0.863	0.934
Neurological			
Multiple sclerosis	1.17 (1.03, 1.32)	0.014	0.041
Alzheimer's disease	1.03 (0.92, 1.16)	0.611	0.764
Migraine —	0.98 (0.84, 1.16)	0.842	0.934
Parkinson's disease	1.09 (0.96, 1.23)	0.175	0.301
Infectious			
Sepsis —	0.94 (0.86, 1.03)	0.221	0.351
Pneumonia	1.07 (0.99, 1.15)	0.078	0.151
Cellulitis	0.98 (0.91, 1.05)	0.485	0.661
Urinary tract infection	1.07 (1.00, 1.14)	0.047	0.103
Tuberculosis	0.97 (0.81, 1.14)	0.688	0.825
0.80 0.90 1.0 1.1 1.2 Odds Ratio per SD lower in IL-18 levels (95% 0	1.3 CI)	32	2